1Sudoh T, Kangwa K, Minamion N, et al. A new natriuretic peptide in porcine brain. Nature, 1988,332 : 78.
2Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid Brain natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. Am Coll Cardiol, 2002,39 : 202-209.
4Toru S, Kazuhide Y, Osamu N , et al. Screening for cardiac dysfunction in asymptomatie patients by measuring B-type natriuretie peptide levels. Jpn Heart J, 2000,41 : 205-214.
5Nielsen OW, Mc-Donagh TA, Robb SD, et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Carol, 2003,41:113-120.
6Maisel AS,Koon J,Krishnaswamy P,et al. Utility of Bnatrluretic pepetide as a rapid, point-of care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J, 2001,141(3):367-374.
7Maisel AS, Krishnaswamy P, Wowak P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure . N Engl J Med, 2002,347: 161-167.
8Dao Q , Krishmaswamyamy P, Kazanegra R, et al. Utility of B-type natriuretic pepetide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Carol, 2001,37 : 379-385.
9Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptide and ejection fraction for prognosis after myocardial infarction. Circulartion, 2003, 107 (22): 2786-2792.
10Ng LL, Loke I, Davies JE, et al. Identification of perviosusly undiagnosed left ventricular systolic dyfunction : community screening using natriuretic peptide and electrocardiography. Eur J Heart Fail, 2003,5(6):755-782.
二级参考文献10
1Collins SP, Ronan-Bentle S, Storrow AB. Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea. Ann Emerg Med, 2003, 41: 532-545.
2Shapiro BP, Chen HH, Burnett JC Jr, et al. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc, 2003, 78:481-486.
3Tjeerdsma G, de Boer RA, Boomsma F, et al. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol,2002, 86:143-149.
4Latini R, Masson S, de Angelis N, et al. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts.J Card Fail, 2002 , 8:288-299.
5Logeart D. Ultra-rapid measurement of brain natriuretic peptide. Arch Mal Coeur Vaiss, 2002, 95:185-188.
6Peacock WF. The B-type natriuretic peptide assay: a rapid test for heart failure. Cleve Clin J Med, 2002, 69:243-251.
7Valli N, Georges A, Corcuff JB, et al. Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data.Clin Chim Acta, 2001,306:19-26.
8Nicholls MG, Lainchbury JG, Richards AM, et al. Brain natriuretic peptide-guided therapy for heart failure. Ann Med, 2001, 33:422-427.
9Sodian R, Loebe M, Schmitt C, et al. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol, 2001, 38:1942-1949.
10Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.Circulation, 2003, 107: 2786-2792.
